Investment Rating - The report does not explicitly provide an investment rating for the industry discussed [2][3]. Core Insights - The NBS Manufacturing PMI for China is expected to decline to 49.6 in April from 50.5 in March, indicating a contraction in manufacturing due to US tariffs and trade uncertainties [3][7]. - Private sector credit in Australia is projected to increase by 0.6% month-on-month in March, leading to an annual growth rate of 6.6% year-on-year [7]. - The Consumer Price Index (CPI) in Australia is anticipated to rise by 0.9% quarter-on-quarter in Q1, maintaining an annual rate of 2.4% year-on-year [7]. - House prices in Australia are expected to see a slight increase in April, supported by expectations of further rate cuts [7]. - Korea's exports are forecasted to decline by 3.6% year-on-year in April, reflecting the impact of steel and auto tariffs [8]. - Taiwan's GDP is projected to rebound to 3.1% year-on-year in Q1, driven by pre-tariff export orders, although a slowdown is expected in Q2 [9]. Summary by Sections Australia - The report anticipates a trade surplus of A$3.8 billion in March, with exports partially rebounding [7]. - Retail sales are expected to increase by 0.1% month-on-month and 4.0% year-on-year in March, marking the strongest annual rate since December 2024 [7]. China - The NBS Manufacturing PMI is expected to soften to 49.6 in April, indicating challenges in production and new orders due to external trade pressures [3][7]. Korea - Exports are expected to show a significant slowdown, with a year-on-year decline of 3.6% in April due to tariff impacts [8]. Taiwan - GDP growth is forecasted to rebound to 3.1% year-on-year in Q1, driven by strong export orders ahead of tariffs [9]. Japan - The Bank of Japan (BOJ) is expected to maintain its current monetary policy stance, with labor market conditions remaining tight [11].

产业的腾飞，离不开优质空间的承载与孵化。福田区创新推出"机器人生态孵化楼宇"计划，旨在助力科 技成果从"实验室"加速走向"应用市场"，为机器人产业集群提供强有力支撑。 作为梅林片区的新地标，华强科创广场定位于以先进制造业为主题的专业产业楼宇，聚焦机器人领 域"硬件研发 + 算法创新"的双轮驱动发展模式，致力于构建集技术攻关、成果转化、产业孵化于一体的 协同创新基地。自建成以来，园区坚持以"湾区智造总部大厦"为战略定位，重点布局智能终端、智能机 器人、半导体与集成电路等战略性新兴产业，通过精准招商构建起完整的高端制造产业生态。 截至目前，园区已形成从核心技术研发到产业化应用的全链条产业集群，展现出强劲的发展动能。此次 获"福田机器人生态孵化楼宇"授牌，标志着园区在智能制造细分领域取得一定进展。这不仅是对园区产 业集聚效应的充分肯定，更是对区域智能制造生态体系的重要补充。园区相关负责人表示，将以此次授 牌为契机，与福田区政府开展更深层次的战略合作，持续优化服务体系，全力打造具有湾区特色的智能 制造示范园区，为区域经济高质量发展注入新动力。 南都讯 记者林敏儿 通讯员蒋蒙 4月25日，作为2025"机器人全产业链接 ...

Core Insights - The 66th National Pharmaceutical Machinery Exposition successfully concluded on April 25, 2025, at Chongqing International Expo Center, organized by HAINAN JING-BO-XIN EXHIBITION CO., LTD. [1] - The exposition attracted 1,686 exhibitors from 24 countries and regions, showcasing over 10,000 products across an exhibition space of 180,000 square meters, with more than 60,000 visitors from 88 countries and regions [3]. Industry Overview - The exposition included a Malaysia-China procurement matchmaking session, facilitating one-on-one meetings between over 20 Chinese manufacturers and six Malaysian pharmaceutical companies [3]. - The organizing committee hosted three thematic forums and 93 technical exchange sessions, featuring keynote speeches from renowned experts and industry professionals [4]. - The Second CIPM Synthetic Biology and Biomanufacturing Industry Development Conference was a significant highlight, attracting over 1,000 professionals from various sectors including pharmaceuticals, food, cosmetics, and pesticides [4]. Historical Context - The China National Pharmaceutical Machinery Exposition has been held biannually since the 1990s and has been recognized as a key exhibition supported by China's Ministry of Commerce since 2004 [5]. - The event expanded in 2008 to include the China International Pharmaceutical Machinery Exposition (CIPM), covering production, processing, packaging, testing, and auxiliary equipment for various industries [5]. - Over the years, CIPM has evolved into a premier global event that integrates trade, technology exchange, and industry dialogue [5].

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

Financial Data and Key Metrics Changes - Total revenue increased year-over-year by more than 4% to €66.4 million, while EBIT for Q1 2025 amounted to €0.6 million [24] - The net result for the quarter was a loss of €0.5 million or €0.01 per share, impacted by unfavorable exchange rate fluctuations [24][37] - Free cash flow was positive, reinforcing the net cash position to €67.7 million, an increase of almost €7 million compared to the beginning of the quarter [24][40] Business Line Data and Key Metrics Changes - Materialise Medical revenue grew almost 19%, driven by both Medical Software and Medical Devices sales, which increased by 14% and 21% respectively [26][29] - Software segment revenue decreased by 6% to €9.8 million due to revenue deferral, although more than 80% of Software revenue was recurring [31][56] - Manufacturing segment revenues decreased by 5.5% compared to Q1 2024, but increased by 12% compared to Q4 2024 [33] Market Data and Key Metrics Changes - Aerospace segment sales grew by 23% year-over-year, while industrial and automotive segments faced challenges [21][33] - The total deferred income position increased to €61 million, with €49 million related to Software licenses and maintenance contracts [40] Company Strategy and Development Direction - The company aims to cut absolute emissions by 55% by 2029 compared to the 2019 baseline, having already reduced emissions by 32% in 2024 [9][10] - Materialise is focusing on scaling additive manufacturing and enhancing software solutions to facilitate broader adoption [11][16] - The company is reassessing its involvement in the defense sector to strengthen its aerospace segment and create new opportunities [22] Management Comments on Operating Environment and Future Outlook - Management expects Q2 to be more challenging but anticipates stabilization in the second half of 2025, maintaining revenue guidance of €270 million to €285 million for the full year [43] - The current geopolitical landscape and macroeconomic conditions are expected to weigh on results, particularly in Q2 [43] Other Important Information - The company launched a clinical trial for a 3D-printed tracheal splint for infants, which could open new market opportunities [15] - Significant R&D investments continued, with over €11 million spent in Q1, primarily in the Medical segments [35] Q&A Session Summary Question: Impact of tariffs on Materialise - Management indicated that the U.S. manufacturing plant mitigates tariff impacts, while raw materials may be affected [48][50] Question: Q2 outlook - Management expects Q2 to be flat on the topline with uncertainty in the market, predicting pressure on the bottom line [52][54] Question: Software revenue performance - Software revenue was below €10 million for the first time since COVID, but over 80% of Software revenue is now recurring, indicating a positive trend [55][56]

Innovative partnership provides clear path for Duke Energy to procure up to 11 American-produced GE Vernova natural gas turbines Partnership ensures Duke Energy will meet its customers' growing and evolving energy needs driven by economic development and AI growth CHARLOTTE, N.C. and CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- Duke Energy (NYSE: DUK) and GE Vernova (NYSE: GEV) announce a significant partnership for natural gas turbines and other associated equipment to meet the growing needs of advan ...

Financial Data and Key Metrics Changes - Total revenue increased by more than 4% year-over-year to €66.4 million in Q1 2025, while EBIT amounted to €600,000, and the net result was a loss of €500,000 or €0.01 per share [17][18][25] - The net cash position at the end of Q1 was €67.7 million, an increase of almost €7 million compared to the beginning of the quarter [17][27] Business Line Data and Key Metrics Changes - Materialise Medical revenue grew by almost 19%, while Software and Manufacturing segments saw revenue decreases of around 6% each [18][20] - Adjusted EBITDA for Materialise Medical increased to over €9 million with a stable margin of 29%, while Software segment adjusted EBITDA decreased to €600,000 with a margin of 6.1% [21][22] Market Data and Key Metrics Changes - The aerospace segment in Manufacturing saw a sales growth of 23% compared to Q1 2024, while overall Manufacturing revenues decreased by 5.5% year-over-year [16][24] - The total deferred revenue related to software maintenance and license fees increased by €1.9 million, totaling almost €49 million [19] Company Strategy and Development Direction - The company aims to scale additive manufacturing and improve efficiency through advanced software solutions, with a focus on overcoming barriers to adoption [9][13] - Materialise is reassessing its involvement in the defense sector to strengthen its position in aerospace and create new opportunities [16] Management Comments on Operating Environment and Future Outlook - Management expects Q2 2025 to be challenging but anticipates stabilization in the second half of the year, maintaining guidance for consolidated revenue between €270 million and €285 million for the full year [29][30] - The transition to a recurring revenue model in the Software segment is progressing, with over 80% of software revenue now recurring [40][42] Other Important Information - The company published its 2024 sustainability report, aiming to cut absolute emissions by 55% by 2029 compared to the 2019 baseline [7][8] Q&A Session Summary Question: Impact of tariffs on Materialise - Management indicated that the US manufacturing plant mitigates tariff impacts, but raw materials may be affected, and the biggest concern is the potential impact on customers [35][36] Question: Outlook for Q2 - Management expects Q2 to be a difficult quarter, with a flattish top line anticipated, but uncertainty remains high [37][38] Question: Software revenue performance - Software revenue was below €10 million for the first time since the beginning of COVID, but deferred revenue is growing, and over 80% of software revenue is now recurring [39][40][41]

Calls for Accountability and Shareholder-Centered ReformBUFFALO, N.Y., April 23, 2025 /PRNewswire/ -- Beaver Hollow Wellness, LLC ("BHW"), the largest active shareholder of Servotronics, Inc. (NASDAQ: SVT), today issued the following statement in response to the Company's amended proxy statement filed April 22, 2025:"Servotronics' latest filing is a clear sign of a board under pressure and out of touch," said Paul L. Snyder III, Chairman of BHW. "The escalation in rhetoric, along with newly inserted languag ...

Steel Dynamics, Inc. (STLD) logged first-quarter 2025 earnings of $1.44 per share, down from $3.67 in the year-ago quarter. However, the bottom line topped the Zacks Consensus Estimate of $1.40.Net sales in the first quarter were down around 6.9% year over year to $4,369.2 million. It beat the Zacks Consensus Estimate of $4,146.2 million.The steel demand strengthened in the first quarter, with customer orders rebounding and backlogs growing steadily across the company’s steel and steel fabrication operation ...

FORT WAYNE, Ind., April 22, 2025 /PRNewswire/ --First Quarter 2025 Performance Highlights: Record steel shipments of 3.5 million tons Net sales of $4.4 billion, operating income of $275 million, and net income of $217 million Adjusted EBITDA of $448 million and cash flow from operations of $153 million, which was reduced by the annual companywide retirement profit-sharing distribution of $165 million in the quarter Strong liquidity of $2.6 billion as of March 31, 2025 Share repurchases of $250 million of th ...